Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer

被引:27
作者
Bhattacharyya, Tapesh [1 ]
Babu, Geethu [2 ]
Kainickal, Cessal Thommachan [2 ]
机构
[1] Tata Med Ctr, Div Radiat Oncol, Kolkata, India
[2] Reg Canc Ctr, Div Radiat Oncol, Trivandrum, Kerala, India
关键词
BARR-VIRUS DNA; PLUS ADJUVANT CHEMOTHERAPY; RANDOMIZED PHASE-II; CONCURRENT CHEMORADIOTHERAPY; THERAPEUTIC GAIN; CARCINOMA; RADIOTHERAPY; TRIAL; MULTICENTER; FRACTIONATION;
D O I
10.1155/2018/3725837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nasopharyngeal carcinoma is highly radio-and chemosensitive tumor with its unique clinical and biological behavior. Treatment of stage I disease is radical radiotherapy alone. For stage II disease treatment is radiotherapy with or without chemotherapy. The standard of care for locally advanced nasopharyngeal cancer (stages III-IVB) is concurrent chemoradiation. Optimum timing and sequence of chemotherapy are not yet well-defined. The role of adjuvant and induction chemotherapy is debatable. Here we are going to highlight the role of chemotherapy in nasopharyngeal carcinoma, its benefit, and controversies regarding timing and sequences.
引用
收藏
页数:7
相关论文
共 36 条
  • [1] Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
    Al-Sarraf, M
    LeBlanc, M
    Giri, PGS
    Fu, KK
    Cooper, J
    Vuong, T
    Forastiere, AA
    Adams, G
    Sakr, WA
    Schuller, DE
    Ensley, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1310 - 1317
  • [2] Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients
    Baujat, B
    Audry, W
    Bourhis, J
    Chan, ATC
    Onat, H
    Chua, DTT
    Kwong, DLW
    al-Sarraf, M
    Chi, KH
    Hareyama, M
    Leung, SF
    Thephamongkhol, K
    Pignon, JP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01): : 47 - 56
  • [3] Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
    Blanchard, Pierre
    Lee, Anne
    Marguet, Sophie
    Leclercq, Julie
    Ng, Wai Tong
    Ma, Jun
    Chan, Anthony T. C.
    Huang, Pei-Yu
    Benhamou, Ellen
    Zhu, Guopei
    Chua, Daniel T. T.
    Chen, Yong
    Mai, Hai-Qiang
    Kwong, Dora L. W.
    Cheah, Shie Lee
    Moon, James
    Tung, Yuk
    Chi, Kwan-Hwa
    Fountzilas, George
    Zhang, Li
    Hui, Edwin Pun
    Lu, Tai-Xiang
    Bourhis, Jean
    Pignon, Jean Pierre
    [J]. LANCET ONCOLOGY, 2015, 16 (06) : 645 - 655
  • [4] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial
    Cao, Su-Mei
    Yang, Qi
    Guo, Ling
    Mai, Hai-Qiang
    Mo, Hao-Yuan
    Cao, Ka-Jia
    Qian, Chao-Nan
    Zhao, Chong
    Xiang, Yan-Qun
    Zhang, Xiu-Ping
    Lin, Zhi-Xiong
    Li, Wei-Xiong
    Liu, Qing
    Qiu, Fang
    Sun, Rui
    Chen, Qiu-Yan
    Huang, Pei-Yu
    Luo, Dong-Hua
    Hua, Yi-Jun
    Wu, Yi-Shan
    Lv, Xing
    Wang, Lin
    Xia, Wei-Xiong
    Tang, Lin-Quan
    Ye, Yan-Fang
    Chen, Ming-Yuan
    Guo, Xiang
    Hong, Ming-Huang
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 14 - 23
  • [5] Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Chan, A. T. C.
    Gregoire, V.
    Lefebvre, J. -L.
    Licitra, L.
    Hui, E. P.
    Leung, S. F.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 83 - 85
  • [6] A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).
    Chan, Anthony T. C.
    Hui, Edwin Pun
    Ngan, Roger K. C.
    Tung, Stewart Yuk
    Cheng, Ashley Chi Kin
    Ng, Wai Tong
    Lee, Victor H. F.
    Ma, Brigette
    Cheng, Hoi Ching
    Wong, Frank C. S.
    Loong, Herbert H. F.
    Tong, Macy
    Poon, Daren M. C.
    Ahuja, Anil Tejbhan
    King, Ann Dorothy
    Wang, Ki
    Mo, Frankie
    Zee, Benny C. Y.
    Chan, Allen K. C.
    Lo, Y. M. Dennis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614
  • [8] Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial
    Chen, Lei
    Hu, Chao-Su
    Chen, Xiao-Zhong
    Hu, Guo-Qing
    Cheng, Zhi-Bin
    Sun, Yan
    Li, Wei-Xiong
    Chen, Yuan-Yuan
    Xie, Fang-Yun
    Liang, Shao-Bo
    Chen, Yong
    Xu, Ting-Ting
    Li, Bin
    Long, Guo-Xian
    Wang, Si-Yang
    Zheng, Bao-Min
    Guo, Ying
    Sun, Ying
    Mao, Yan-Ping
    Tang, Ling-Long
    Chen, Yu-Ming
    Liu, Meng-Zhong
    Ma, Jun
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 150 - 158
  • [9] Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
    Chen, Lei
    Hu, Chao-Su
    Chen, Xiao-Zhong
    Hu, Guo-Qing
    Cheng, Zhi-Bin
    Sun, Yan
    Li, Wei-Xiong
    Chen, Yuan-Yuan
    Xie, Fang-Yun
    Liang, Shao-Bo
    Chen, Yong
    Xu, Ting-Ting
    Li, Bin
    Long, Guo-Xian
    Wang, Si-Yang
    Zheng, Bao-Min
    Guo, Ying
    Sun, Ying
    Mao, Yan-Ping
    Tang, Ling-Long
    Chen, Yu-Ming
    Liu, Meng-Zhong
    Ma, Jun
    [J]. LANCET ONCOLOGY, 2012, 13 (02) : 163 - 171
  • [10] Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
    Chen, Qiu-Yan
    Wen, Yue-Feng
    Guo, Ling
    Liu, Huai
    Huang, Pei-Yu
    Mo, Hao-Yuan
    Li, Ning-Wei
    Xiang, Yan-Qun
    Luo, Dong-Hua
    Qiu, Fang
    Sun, Rui
    Deng, Man-Quan
    Chen, Ming-Yuan
    Hua, Yi-Jun
    Guo, Xiang
    Cao, Ka-Jia
    Hong, Ming-Huang
    Qian, Chao-Nan
    Mai, Hai-Qiang
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (23): : 1761 - 1770